{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=L-Asparaginase", "query": { "intervention": "L-Asparaginase" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 163, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=L-Asparaginase&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T16:47:40.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00866749", "title": "Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Intrathecal Methotrexate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 120, "start_date": "2006-09-12", "completion_date": "2018-07-26", "has_results": true, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866749" }, { "nct_id": "NCT00693602", "title": "Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Non Hodgkins Lymphoma" ], "interventions": [ { "name": "Erwinase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 87, "start_date": "2006-06", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693602" }, { "nct_id": "NCT02003222", "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 488, "start_date": "2014-05-19", "completion_date": "2027-02-25", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 531, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003222" }, { "nct_id": "NCT01643408", "title": "A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "asparaginase Erwinia chrysanthemi", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 30, "start_date": "2012-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange County, California • Palo Alto, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange County", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643408" }, { "nct_id": "NCT00369317", "title": "Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Basophilic Leukemia", "Childhood Acute Eosinophilic Leukemia", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Childhood Myelodysplastic Syndromes", "de Novo Myelodysplastic Syndromes", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "4 Years", "sex": "ALL", "summary": "Up to 4 Years" }, "enrollment_count": 205, "start_date": "2007-03", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2022-01-28", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 88, "location_summary": "Phoenix, Arizona • Downey, California • Long Beach, California + 73 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369317" }, { "nct_id": "NCT01403415", "title": "Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood B Acute Lymphoblastic Leukemia", "Childhood T Acute Lymphoblastic Leukemia", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 13, "start_date": "2011-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-07-10", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403415" }, { "nct_id": "NCT00928200", "title": "Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Lymphoblastic Leukemia", "Allergy to PEG e.Coli Asparaginase", "Allergy to Native e.Coli Asparaginase" ], "interventions": [ { "name": "Erwinase", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Triple Intrathecal Therapy", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 1, "start_date": "2009-04-13", "completion_date": "2010-06-04", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928200" }, { "nct_id": "NCT02521493", "title": "Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Down Syndrome", "Myelodysplastic Syndrome", "Myeloid Leukemia Associated With Down Syndrome", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Asparaginase", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "91 Days", "maximum_age": "3 Years", "sex": "ALL", "summary": "91 Days to 3 Years" }, "enrollment_count": 280, "start_date": "2015-12-23", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 169, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02521493" }, { "nct_id": "NCT03150693", "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pegylated L-Asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 303, "start_date": "2017-09-20", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150693" }, { "nct_id": "NCT03808610", "title": "Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-04-03", "completion_date": "2026-05-05", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-13T16:47:40.983Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03808610" } ] }